Astra Zeneca nådde inte mål i lungcancerstudie

Collaboration in laboratory automation

The Dutch company Synchron Lab Automation developed an automated DNA extraction system with high throughput, working very closely together with Festo. As a resu...

Vaccine skeptic David Geier to lead study on link to autism

The American government is to launch a study on whether vaccines cause autism – and has appointed a well-known vaccine skeptic to lead the analysis.

Non-destructive testing and assembly control

Assess complete assembly.

She is CSL Behring's new Nordic General Manager

Since the beginning of january, Helena Bragd is the new Nordic General Manager for the biotech company CSL Behring and CEO of CSL Behring AB.

Toppnamn till Smartcellas styrelse

KI-professorn Anna Martling och Regina Fritsche-Danielson, vetenskaplig ledare för Astra Zenecas forskningsanläggning i Göteborg, tar bägge plats i biotech- och...

Lucy Robertshaw: Artificial intelligence – is this really going to transform a patient’s life?

In a column Lucy Robertshaw reflects on how AI and new regulations will affect healthcare, innovation and the lives of future patients.

Astra Zeneca föll efter besvikelser i rapport

Läkemedelsjätten Astra Zeneca föll rejält på börsen på torsdagen efter ett något sämre resultat än väntat det fjärde kvartalet 2023. Samtidigt presenterar bolag...

Moderna develops mRNA vaccine against norovirus

A highly anticipated vaccine is in late clinical evaluation and could be ready for approval within a couple of years. The target is the norovirus, often called ...

LINK Medical recruits Swedish CEO

The Norwegian Contract Research Organization LINK Medical has recruited Anders Göransson as the new CEO.

Radioaktivt spårämne ska visa effekt av läkemedel mot tarmsjukdom

En radioaktiv markör som utvecklats av Astra Zeneca och Karolinska institutet kan spela en stor roll för patienter med Crohns sjukdom. Det menar Maria Belvisi, Astra Zeneca.

The new Astra Zeneca CEO: “An incredibly exciting phase”

Almost 27 years have passed since Per Alfredsson from Södertälje stepped into Astra Zeneca as a newly hired engineer. After countless different roles, including...

Standardisation in automation

B. Braun Melsungen had a great idea and implemented it throughout the plant. Production for infusion solutions was to be largely standardised. B. Braun hoped th...

ZEISS continues to drive digital era forward in ophthalmology

2 million digitally planned cataract cases in the U.S. alone.

Anna Törner: Kalashnikovs in a new guise

Thanks to resisting European regulatory authorities, Europe has been spared the opioid epidemic. In the 1960s, the situation was the opposite as the American ph...

“A major energy boost for the entire cancer vaccine field”

The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment l...

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

Hello Angelica Loskog!

Life Science Sweden would like to know more about Angelica Loskog and interviews her about her life as a researcher.

Extremely high sample throughput rates

Precision and reliability in automated liquid handling

Astra Zeneca-samarbete ska gynna start up-bolag i Sverige och Norge

Ett nytt samarbete har ingåtts mellan Astra Zeneca, Oslo Cancer Cluster och Oslo Science City. Syftet är att främja kontakter och samarbete mellan norska och sv...

Lilly recruits top Swedish researcher in Alzheimer´s

One of Sweden's leading Alzheimer's researchers, Oskar Hansson, has been recruited by pharma giant Eli Lilly and will be moving to the USA.

Lucy Robertshaw: Are we in the perfect storm?

“Is there a perfect storm on the horizon again as elective surgeries were cancelled due to patients being admitted with Covid-19? We now have a long backlog of ...

Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”

It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic hav...

Medivir i samarbete med Eisai om levercancerkandidat

Medivir har ingått ett samarbetsavtal med det japanska läkemedelsbolaget Eisai om en klinisk studie som ska pröva en kombination av de bägge bolagens terapier mot levercancer.